Bethany Sensenig
Known title: DirectorCIK: 0001899935
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Supernus mentioned in healthcare stock screening article. Supernus Pharmaceuticals was included in a recent Yahoo Finance article discussing healthcare stocks. The piece highlights specific names for investor attention while noting others to avoid, providing context for the company's current market visibility. This media coverage adds to the narrative surrounding the stock without introducing new fundamental data.
Transaction History
| ACOG | ▲ Buy | Grant | 5,489 | $0 | 4/16/2026 | View on chart |
| SUPN | ▲ Buy | Option Exercise | 4,475 | $0 | 2/19/2026 | View on chart |
| SUPN | ▼ Sell | Open Market | 1,217 | $61K | 2/19/2026 | View on chart |
| SUPN | ▼ Sell | Open Market | 3,258 | $167K | 2/19/2026 | View on chart |
| SUPN | ▼ Sell | Open Market | 5,369 | $227K | 8/14/2025 | View on chart |
| SUPN | ▲ Buy | Grant | 5,369 | $0 | 2/22/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Alpha Cognition Releases 180-Day Data on CONVERGE Program
Alpha Cognition has published results from a 180‑day study of its CONVERGE program. The data covers patients who are taking ZUNVEYL, donepezil, galantamine or rivastigmine. The release gives a clearer view of how the program performs in real‑world use. Investors can use the information to assess the company’s therapeutic strategy.
Alpha Cognition Releases 180-Day Data on CONVERGE Program. Alpha Cognition has published results from a 180‑day study of its CONVERGE program. The data covers patients who are taking ZUNVEYL, donepezil, galantamine or rivastigmine. The release gives a clearer view of how the program performs in real‑world use. Investors can use the information to assess the company’s therapeutic strategy.